Year-End Report
STANTON PARK GROUP for BARR LABORATORIES
Firm
Client
Income
$60,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Consumer Issues/Safety/Products CSP
Generic Drug Settlements (S 316, HR 1902)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN CAVEY | N/A |
| JAMES DERDERIAN | N/A |
| ANDREW HALATAEI | N/A |
| ERIN STRAWN | N/A |
| ASHLIE VAN METER | N/A |
Pharmacy PHA
Generic Biologics (HR 1956, S 1695, HR 1038, S 623); FDA Reform (HR 2900, S 1082); Ofice of Generic Drugs funding in Agrigulture Appropriations (HR 3161, S 1859)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN CAVEY | N/A |
| JAMES DERDERIAN | N/A |
| ANDREW HALATAEI | N/A |
| ERIN STRAWN | N/A |
| ASHLIE VAN METER | N/A |
Science/Technology SCI
Patent Reform (HR 1908, S 1145)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN CAVEY | N/A |
| JAMES DERDERIAN | N/A |
| ANDREW HALATAEI | N/A |
| ERIN STRAWN | N/A |
| ASHLIE VAN METER | N/A |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.